Fmoc-Lys(Z)-OSu | 116064-01-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: Fmoc-Lys(Z)-OSu
• 英文别名: (2,5-dioxopyrrolidin-1-yl) (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-6-(phenylmethoxycarbonylamino)hexanoate
• CAS: 116064-01-8
• 化学式: C₃₃H₃₃N₃O₈
• 分子量: 599.64
• InChiKey: FSODHUJMRNTQJS-NDEPHWFRSA-N

物化性质

• 熔点：
  115 °C(Solv: ethyl acetate (141-78-6))
• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  44.0
• 可旋转键数：
  12.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  140.34
• 氢给体数：
  2.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  (S)-2-amino-6-(tert-butoxycarbonylamino)hexanoic acid 、 Fmoc-Lys(Z)-OSu 在 碳酸氢钠 作用下， 以 乙腈 为溶剂， 生成 KK dimer
  参考文献：
  名称：

  Mitigating the Immunogenicity of AAV-Mediated Gene Therapy with an Immunosuppressive Phosphoserine-Containing Zwitterionic Peptide

  摘要：

  DOI：

  10.1021/jacs.2c09484
• 作为产物：
  描述：

  N-羟基丁二酰亚胺 、 N'-芴甲氧羰基-N-苄氧羰基-L-赖氨酸 在 N,N'-二环己基碳二亚胺 作用下， 以 乙腈 为溶剂， 生成 Fmoc-Lys(Z)-OSu
  参考文献：
  名称：

  Mitigating the Immunogenicity of AAV-Mediated Gene Therapy with an Immunosuppressive Phosphoserine-Containing Zwitterionic Peptide

  摘要：

  DOI：

  10.1021/jacs.2c09484

文献信息

• Convergent solid phase peptide synthesis. v. synthesis of the 1-4, 32-34, and 53-59 protected segments of the toxin ii of androctonus australis hector.
  作者：F. Albericio、E. Nicolás、J. Josa、A. Grandas、E. Pedroso、E. Giralt、C. Granier、J. van Rietschoten

  DOI：10.1016/s0040-4020(01)87802-9

  日期：——
• Searching for improved mimetic peptides inhibitors preventing conformational transition of amyloid-β42 monomer
  作者：János Gera、Titanilla Szögi、Zsolt Bozsó、Livia Fülöp、Exequiel E. Barrera、Ana M. Rodriguez、Luciana Méndez、Carina M.L. Delpiccolo、Ernesto G. Mata、Federica Cioffi、Kerensa Broersen、Gabor Paragi、Ricardo D. Enriz

  DOI：10.1016/j.bioorg.2018.08.018

  日期：2018.12

  A series of novel mimetic peptides were designed, synthesised and biologically evaluated as inhibitors of A beta(42) aggregation. One of the synthesised peptidic compounds, termed compound 7 modulated A beta(42) aggregation as demonstrated by thioflavin T fluorescence, acting also as an inhibitor of the cytotoxicity exerted by A beta(42) aggregates. The early stage interaction between compound 7 and the A beta(42) monomer was investigated by replica exchange molecular dynamics (REMD) simulations and docking studies. Our theoretical results revealed that compound 7 can elongate the helical conformation state of an early stage A beta(42) monomer and it helps preventing the formation of beta-sheet structures by interacting with key residues in the central hydrophobic cluster (CHC). This strategy where early "on-pathway" events are monitored by small molecules will help the development of new therapeutic strategies for Alzheimer's disease.
• ALBERICIO, F.;NICOLAS, E.;JOSA, J.;GRANDAS, A.;PEDROSO, E.;GIRALT, E.;GRA+, TETRAHEDRON, 43,(1987) N 24, 5961-5971
  作者：ALBERICIO, F.、NICOLAS, E.、JOSA, J.、GRANDAS, A.、PEDROSO, E.、GIRALT, E.、GRA+

  DOI：——

  日期：——